USFDA Grants Approval To Aurobindo Pharma's Generic Dasatinib Tablets For Cancer Treatment
The product is expected to be launched in first quarter of fiscal 2026, Aurobindo Pharma said.
(Representative image. Source: Unsplash)
Aurobindo Pharma Ltd on Wednesday said its wholly- owned arm Eugia Pharma Specialities Ltd has received final approval from the USFDA to manufacture and market its generic version of Dasatinib tablets indicated in certain types of cancer of bone marrow and blood.
The approval by the US Food & Drug Administration is for manufacturing and marketing of Dasatinib tablets of strengths 20 mg, 50 mg, 70 mg, 80 mg, 100 mg, and 140 mg, Aurobindo Pharma said in a regulatory filing.
These are bioequivalent and therapeutically equivalent to the reference listed drug Sprycel Tablets in the same strengths, of Bristol-Myers Squibb Company, it added.
The product is expected to be launched in first quarter of fiscal 2026, Aurobindo Pharma said.
The approved product has an estimated market size of $1.8 billion for the 12 months ended February 2025, it said citing IQVIA MAT data.
